Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

Journal of Neuro-Oncology

Volumn 108, Issue 3, 2012, Pages 499-506

  Reardon, David A ^a,b   Vredenburgh, James J ^b   Desjardins, Annick ^b   Peters, Katherine B ^b   Sathornsumetee, Sith ^c   Threatt, Stevie ^b   Sampson, John H ^b   Herndon II, James E ^b   Coan, April ^b   McSherry, Frances ^b   Rich, Jeremy N ^d   McLendon, Roger E ^b   Zhang, Steven ^e   Friedman, Henry S ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d LERNER RESEARCH INSTITUTE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dasatinib; Epidermal growth factor receptor (EGFR); Erlotinib; Glioblastoma; Malignant glioma

Indexed keywords

ANTICONVULSIVE AGENT; DASATINIB; DEXAMETHASONE; ENZYME INDUCING AGENT; ENZYME INDUCING ANTIEPILEPTIC AGENT; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN RADIOGRAPHY; CANCER GRADING; CANCER PATIENT; COHORT ANALYSIS; DIARRHEA; DOSE LIMITING TOXICITY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRIMIDINES; QUINAZOLINES; THIAZOLES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84864042721     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0848-x     Document Type: Article

References (33)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
2. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma mul-tiforme. Neuro-Oncology 9:29-38 (Pubitemid 46543486)
3. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology 10:162-170
4. Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR, Jaeckle KA, Prados MD (2010) Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology 12:164-172. doi:10.1093/neuonc/ nop019
5. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, Yung WKA, Bogler O, Weinstein JN, Berg V, Berger M, Prados M, Muzny D, Morgan M, Scherer S, Sabo A (2008) Comprehensive genomic characterization defines human glio-blastoma genes and core pathways. Nature 455:1061-1068
6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
7. Shepherd FA, Pereira RJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erl-otinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
9. Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, Men A, Noory C, Ramchandani R, Kenna L, Booth B, Gobburu J, Jiang X, Sridhara R, Justice R, Pazdur R (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14:352-359. doi:10.1158/1078-0432.CCR-07-4175 (Pubitemid 351226100)
10. Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 8:67-78 (Pubitemid 43154453)
11. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
12. Eley T, Luo FR, Agrawal S, Sanil A, Manning J, Li T, Black-wood-Chirchir A, Bertz R (2009) Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 49:700-709. doi:10.1177/ 0091270009333854
13. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G (2010) Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28:1387-1394. doi:10.1200/ JCO.2009.25.4029
14. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology 12:95-103
15. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142 (Pubitemid 41095125)
16. Van Den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recur-rent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27:1268-1274
17. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: north American brain tumor consortium study 99-08. Clin Cancer Res 12:4899-4907 (Pubitemid 44338577)
18. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Kle-ncke B, Gilbert MR, Reardon DA, Prados MD (2010) Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology 12:1061-1070. doi:10.1093/neuonc/ noq072
19. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multi-forme. Invest New Drugs 23:357-361 (Pubitemid 40980358)
20. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294-5304 (Pubitemid 46206983)
21. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine 5:e8
22. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Arm-strong EA, Li C, Wheeler DL (2011) Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30:561-574. doi:10.1038/onc.2010.430
23. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84:6899-6903
24. Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR (2009) Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27:77-83. doi:10.1038/nbt.1513
25. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK (2010) Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 9:1298-1307. doi:10.1158/ 1535-7163.MCT-09-0707
26. Stettner MR, Wang W, Nabors LB, Bharara S, Flynn DC, Grammer JR, Gillespie GY, Gladson CL (2005) Lyn kinase activity is the predominant cellular SRC kinase activity in glio-blastoma tumor cells. Cancer Res 65:5535-5543. doi:10.1158/ 0008-5472.CAN-04-3688 (Pubitemid 40911153)
27. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL (2008) The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 68:1862-1871. doi:10.1158/0008-5472.CAN-07-1182 (Pubitemid 351416572)
28. Milano V, Piao Y, LaFortune T, de Groot J (2009) Dasatinib-induced autophagy is enhanced in combination with temozolo-mide in glioma. Mol Cancer Ther 8:394-406. doi:10.1158/1535-7163.MCT-08-0669
29. Lund CV, Nguyen MT, Owens GC, Pakchoian AJ, Shaterian A, Kruse CA, Eliceiri BP (2006) Reduced glioma infiltration in Src-deficient mice. J Neurooncol 78:19-29 (Pubitemid 43786654)
30. Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Wen PY (2011) Retrospective study of dasatinib for recurrent glioblas-toma after bevacizumab failure. J Neurooncol 104:287-291. doi: 10.1007/s11060-010-0489-x
31. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116:1582-1591. doi:10.1002/cncr.24927
32. Shayani S (2010) Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events. Ther Drug Monit 32:680-687. doi:10.1097/FTD.0b013e3181f4d9c5
33. Dong PP, Fang ZZ, Zhang YY, Ge GB, Mao YX, Zhu LL, Qu YQ, Li W, Wang LM, Liu CX, Yang L (2011) Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacol Sin 32:399-407. doi:10.1038/ aps.2010.218